How does the MFX-T bioreactor increase transduction efficiency? 💡 By using microfluidic channels, we reduce the distance that viral particles and activation reagents need to travel, increasing the likelihood of interactions with cells. Transduction can happen faster and more efficiently. Want to try the Cyto Engine technology for yourself? We're collaborating with a limited number of companies to trial the MFX-T Transduction Bioreactor in our Early Access Program. Apply now https://bit.ly/45OBDMe #ATMP #microfluidics #bioreactor #celltherapy #genetherapy #cellandgenetherapy #cytoengine #MFX
MFX
Automation Machinery Manufacturing
Stevenage, England 4,548 followers
The Cyto Engine - industrializing cell and gene therapy manufacturing
About us
MFX presents the Cyto Engine, a unified bioreactor and data platform for cell and gene therapy research, development, and manufacturing
- Website
-
http://www.mfx.bio
External link for MFX
- Industry
- Automation Machinery Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Stevenage, England
- Type
- Privately Held
- Founded
- 2020
- Specialties
- microfluidics, cell and gene therapy, cell and gene therapy manufacturing, automation, process analytical technology, cell culture, and process development
Locations
-
Primary
Gunnels Wood Road
Stevenage Biosciences Catalyst
Stevenage, England, GB
Employees at MFX
Updates
-
Last month alongside Stevenage Bioscience Catalyst and The Honeycomb Works we supported The CGT Circle to put on their first ever workshop event aimed at all who wanted to learn about building inclusive cultures as a celebration of #Pride If you missed it - don't worry we have you covered - here's our recap of this informative and engaging afternoon! #inclusivity #culture #learning #cellandgenetherapy
-
MFX reposted this
James Kusena PhD is Vice President of Operations & Product Owner at MFX, a company developing research and manufacturing tools to serve the cell and gene therapy industry. Which came first, the tools or the research? James talks about the impact on the drug development industry of CAR-T therapies. These therapies have made it through the approval process which means that both investors and companies are now willing to spend to develop both new therapies and, importantly, the tools and processes that support them. James’ challenge at MFX is surveying the industry’s wide range approaches, new ways of using different cell types continue to be investigated. MFX identifies the common issues that can be addressed in the bioprocessing and develops tools to enable these cell and gene therapies to produce in sufficient, cost effective quantities with robust quality so they can enter the clinic. James will be speaking at ELRIG’s Drug Discovery 2024 on Thursday 3rd October in the track Innovation in Cell and Gene Therapy Development and Manufacturing – supported by the Cell and Gene Therapy Catapult. Register here: https://lnkd.in/ePmtmfN9 #CellTherapy #GeneTherapy #Networking #Innovation #MFX #CytoEngine #CellandGeneTherapy #Bioprocessing
-
Quality control is essential, but traditional QC processes make it tricky to work at a large scale when manufacturing CGTs. We are thinking of solutions to this larger-than-life puzzle. Read more at: https://bit.ly/3VMJQvT #qualitycontrol #scale #CGTs #mfx
-
The core of the Cyto Engine technology is our scalable bioreactor cassettes. So how do we make sure the way cells behave at smaller volumes translates to bigger volumes? 🎚️ Precision fluidic control: we use our microfludic know-how to precisely control the cellular environment 🔁 Parallelisation: we copy and paste that same fluidic environment, meaning that cells growing in our large bioreactor cassettes grow the same as in our smaller ones Instant scalability for your process. Want to try the Cyto Engine technology for yourself? We're collaborating with a limited number of companies to trial the MFX-T Transduction Biorector in our Early Access Program. Apply now https://bit.ly/4cIpXwM #ATMP #microfluidics #bioreactor #celltherapy #genetherapy #cellandgenetherapy #cytoengine #MFX
-
Lindsey Clarke will be joining her The CGT Circle co-founders Kate Fynes and Nicola Ambler at Phacilitate Women in Advanced Therapies next week! They'll be taking stock of the insights gained and lessons learned over the past year at the CGT circle panel session on July 10th 2024 at 4.30pm Register for the free WIAT Global event here 👉 Women in Advanced Therapies Global - https://bit.ly/45RSjSV #womeninadvancedtherapies #womeninscience #cgtcircle #WIATglobal #MFX
-
With our early access program to test the power of microfluidics on your transduction process fully open - We’ve been stocking up on kits ready to ship out! Want to be the first to try this simple solution to a big challenge? Register for more info at the link in the comments ⏬⏬⏬ You can find out more and check out our latest data on the newly updated webpages: https://bit.ly/3KUKjqX #cellandgenetherapy #mfx #innnovation#transduction
-
Today’s the day! We’re super excited to be supporting The CGT Circle event this afternoon with Stevenage Bioscience Catalyst and The Honeycomb Works So much so we got branded cupcakes!
-
Want to know the team behind the Cyto Engine? We asked Nabilla Farah Naura, our Commercial Intern, and San-Chi Chen, our Bioprocessing intern, 5 questions about themselves and what they do at MFX. Both of our amazing interns are undertaking the Manufacture and Commercialisation of Stem Cells and Gene Therapies MSc - a brilliant program providing key skills, practical training and expertise to develop future generations of engineers, scientists and business professionals, directed by Qasim Rafiq at UCL. #team #insights #MFX
-
It’s been an extremely busy month at MFX! Our first batch of MFX-12 (Research Engine) bioreactors came off the production line so it’s been all hands on deck to finish them off inhouse - quite literally with even our co-founders Césaré Cejas, PhD, MBA and Antoine Espinet getting a turn under strict supervision from the production technicians Tom Phillips-Hall and Noman Naeem All ready for some serious biological testing both internally and with our early access partners - we can't wait! #cellandgenetherapy #innovation